Is Coya Therapeutics, Inc. (COYA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 38.3% / 30% | 0.7% / 30% | 46.39% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 38.3% / 33% | 0.7% / 33% | 46.39% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 86.5% / 33% | 1.6% / 33% | 46.39% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 38.3% / 33% | 0.7% / 33% | 46.39% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 86.5% / 33% | 1.6% / 50% | 46.39% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -110.6% | |
| Operating Margin | -107.5% | |
| Net Margin | -267.1% | |
| Return on Equity (ROE) | -51.4% | |
| Return on Assets (ROA) | -26.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$11M |
| Free Cash Flow | -$11M |
| Current Ratio | 8.5 |
| Total Assets | $50M |
Price & Trading
| Last Close | $4.18 |
| 50-Day MA | $4.64 |
| 200-Day MA | $5.65 |
| Avg Volume | 203K |
| Beta | 0.2 |
|
52-Week Range
$3.91
| |
About Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Coya Therapeutics, Inc. (COYA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Coya Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Coya Therapeutics, Inc.'s debt ratio?
Coya Therapeutics, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Coya Therapeutics, Inc.'s key financial metrics?
Coya Therapeutics, Inc. has a market capitalization of $93M, and revenue of $8M. The company maintains a gross margin of -110.6% and a net margin of -267.1%. Return on equity stands at -51.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.